Tricida to Participate in Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Tricida, a pharmaceutical company focused on chronic kidney disease (CKD), will participate in the Kidney Disease / Fibrosis panel at the Cowen 42^nd Annual Health Care Conference. The discussion is scheduled for March 9, 2022, at 11:10 am PT / 2:10 pm ET. The company is developing veverimer, a non-absorbed polymer aimed at slowing CKD progression. Currently, there are no FDA-approved therapies for metabolic acidosis in CKD patients, affecting approximately three million people in the U.S. A live webcast of the panel will be available on Tricida's website.

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD, announced today that it will participate in a Kidney Disease / Fibrosis panel discussion at the Cowen 42^nd Annual Health Care Conference on Wednesday, March 9, 2022 at 11:10 am PT / 2:10 pm ET.

A live webcast of the panel discussion will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. There are currently no therapies approved by the FDA to slow progression of kidney disease through the treatment of chronic metabolic acidosis in patients with CKD. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Vice President of Investor Relations and Communications
IR@Tricida.com 

FAQ

What is the purpose of Tricida's panel discussion at the Cowen Health Care Conference?

Tricida's panel discussion aims to address issues related to kidney disease and fibrosis, focusing on its investigational drug veverimer.

When is Tricida's panel discussion scheduled?

The panel discussion is scheduled for March 9, 2022, at 11:10 am PT / 2:10 pm ET.

How can I watch Tricida's panel discussion?

The panel discussion will be available via live webcast on Tricida's website.

What is veverimer and its significance for CKD patients?

Veverimer is an investigational drug intended to slow the progression of chronic kidney disease in patients with metabolic acidosis.

Why is veverimer important for patients with CKD?

Veverimer targets metabolic acidosis, a condition that can accelerate kidney deterioration in CKD patients, with no current FDA-approved therapies available.